Importantly, using in vivo mouse models and patient-derived AML and ACC cells these studies have provided evidence that MYB inhibition may be effective against AML and ACC [36,37,38,39,40,41,42]. The gene discussed is MYB; the disease is adrenal cortex carcinoma.